Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis

A E Holland, L Denehy, G Ntoumenopoulos, M T Naughton, J W Wilson, A E Holland, L Denehy, G Ntoumenopoulos, M T Naughton, J W Wilson

Abstract

Background: Chest physiotherapy is essential to the management of cystic fibrosis (CF). However, respiratory muscle fatigue and oxygen desaturation during treatment have been reported. The aim of this study was to determine whether non-invasive ventilation (NIV) during chest physiotherapy could prevent these adverse effects in adults with exacerbations of CF.

Methods: Twenty six patients of mean (SD) age 27 (6) years and forced expiratory volume in 1 second (FEV1) 34 (12)% predicted completed a randomised crossover trial comparing standard treatment (active cycle of breathing technique, ACBT) with ACBT + NIV. Respiratory muscle strength (PImax, PEmax), spirometric parameters, and dyspnoea were measured before and after treatment. Pulse oximetry (SpO2) was recorded during treatment. Sputum production during treatment and 4 and 24 hours after treatment was evaluated.

Results: There was a significant reduction in PImax following standard treatment that was correlated with baseline PImax (r=0.73, p<0.001). PImax was maintained following NIV (mean difference from standard treatment 9.04 cm H2O, 95% confidence interval (CI) 4.25 to 13.83 cm H2O, p=0.006). A significant increase in PEmax was observed following the NIV session (8.04 cm H2O, 95% CI 0.61 to 15.46 cm H2O, p=0.02). The proportion of treatment time with SpO2 < or =90% was correlated with FEV1 (r=-0.65, p<0.001). NIV improved mean SpO2 (p<0.001) and reduced dyspnoea (p=0.02). There were no differences in FEV1, forced vital capacity (FVC) or sputum weight, but FEF(25-75) increased following NIV (p=0.006).

Conclusion: Reduced inspiratory muscle strength and oxygen desaturation during chest physiotherapy are associated with inspiratory muscle weakness and severity of lung disease in adults with exacerbations of CF. Addition of NIV improves inspiratory muscle function, oxygen saturation and small airway function and reduces dyspnoea.

References

    1. Am Rev Respir Dis. 1973 Jan;107(1):130-2
    1. Pediatr Pulmonol. 1995 Jan;19(1):16-22
    1. Thorax. 1984 Jul;39(7):535-8
    1. Am Rev Respir Dis. 1985 Oct;132(4):766-9
    1. Pediatr Pulmonol. 1986 Nov-Dec;2(6):358-67
    1. Thorax. 1990 Jan;45(1):77
    1. Am Rev Respir Dis. 1993 Apr;147(4):865-9
    1. Chest. 1993 Jun;103(6):1819-25
    1. Am J Respir Crit Care Med. 1994 May;149(5):1069-76
    1. Am J Respir Crit Care Med. 1994 Jul;150(1):66-71
    1. Chest. 1994 Dec;106(6):1872-82
    1. Thorax. 1995 Feb;50(2):165-9
    1. Crit Care Med. 1996 Nov;24(11):1920-9
    1. Chest. 1998 Apr;113(4):1013-8
    1. Respir Med. 1998 Mar;92(3):523-6
    1. Pediatrics. 1999 Mar;103(3):E32
    1. J Heart Lung Transplant. 1999 Mar;18(3):255-65
    1. Eur Respir J. 1999 Jun;13(6):1477-86
    1. Respiration. 2000;67(6):595-607
    1. Respir Med. 1999 Sep;93(9):660-5
    1. Chest. 2000 Nov;118(5):1286-93
    1. Eur Respir J. 2001 Apr;17(4):712-5
    1. Aust J Physiother. 2001;47(4):227-36
    1. J Pediatr. 2002 Feb;140(2):156-64
    1. Exerc Sport Sci Rev. 1974;2:131-53

Source: PubMed

3
Se inscrever